首页> 美国卫生研究院文献>BioMed Research International >Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment
【2h】

Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment

机译:肥厚型心肌病-左室流出道梯度的梗阻形式:激发的新方法,生物标志物的监测和治疗的新进展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dynamic (latent or/and labile) obstruction of left ventricular outflow (LVOT) was recognized from the earliest clinical descriptions of hypertrophic cardiomyopathy (HCM) and has proved to be a complex phenomenon, as well as arguably the most audible (“visible”) pathophysiological hallmark of this heterogeneous disease. The aim of the current review is focused on two novel issues in a subgroup of obstructive HCM. Firstly, the important methodological problem in HCM is the examination of a subgroup of patients with nonobstructive hypertrophy in resting conditions and hard, but possible provoking obstruction. Recently, investigators have proposed physiological stress test (with double combined stimuli) to disclose such type of patients. The upright exercise is described in the ESC guideline on hypertrophic cardiomyopathy from 2014 and may appear as a candidate for gold standard provocation test. The second novel area of interest is associated with elevated level of signaling biomarkers: hypercoagulation, hemolysis, acquired von Willebrand 2A disease, and enhanced oxidative stress. The accelerated and turbulent flow within narrow LVOT may be responsible for these biochemical disturbances. The most recent advances in the treatment of obstructive HCM are related to nonpharmacological methods of LVOT gradient reduction. This report extensively discusses novel methods.
机译:最早的肥厚型心肌病(HCM)临床描述认识到动态性(潜在或/和不稳定)左室流出道梗阻(LVOT),已被证明是一种复杂的现象,并且可以说是最容易听到的(“可见”)这种异质性疾病的病理生理学标志。本综述的目的是针对阻塞性HCM子组中的两个新问题。首先,HCM的重要方法学问题是检查在休息条件下有硬性但可能引起阻塞的非阻塞性肥厚患者亚组。最近,研究人员提出了生理压力测试(带有双重组合刺激)来揭示这类患者。 ESC指南自2014年起针对肥厚型心肌病进行了直立锻炼,该锻炼可能会成为金标准激发试验的候选人。第二个感兴趣的新领域与信号生物标志物水平升高有关:过度凝结,溶血,后天性von Willebrand 2A疾病和氧化应激增强。狭窄的LVOT内的加速流动和湍流可能是造成这些生化干扰的原因。阻塞性HCM治疗的最新进展与降低LVOT梯度的非药物方法有关。本报告广泛讨论了新颖的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号